Prime Medicine said an arbitration panel ruled in its favor in a gene-editing dispute with Beam Therapeutics, concluding Prime did not violate a 2019 agreement tied to competing development. The ruling specifically allows Prime to continue work on its alpha-1 antitrypsin deficiency (AATD) program. Prime indicated the decision paves the way to start a clinical trial for AATD in the current quarter, lifting its earlier uncertainty around contractual constraints. Beam’s posture is framed as impaired by the arbitrator’s outcome. The case highlights how IP and contract interpretation can directly determine whether gene-editing assets move into the clinic, independent of scientific progress.